文献速递消化、代谢与肾脏急症心脑血管急症

撤稿:羟氯喹或氯喹联合或不联合大环内酯类药物治疗COVID-19:一项多国注册研究分析

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.
PubMed 文献 · Lancet · 2020-05-22
一句话结论多国注册分析显示,羟氯喹或氯喹单用或联用大环内酯类治疗COVID-19与住院死亡率及室性心律失常风险升高独立相关,未能证实获益。

该多国注册研究纳入671家医院、6大洲的96032例COVID-19住院患者,比较羟氯喹或氯喹单用或联用大环内酯类的四种方案与对照组。在校正多因素后,各治疗组住院死亡率(18.0%-23.8%)均高于对照组(9.3%),新发室性心律失常发生率(4.3%-8.1%)也高于对照组(0.3%)。作者结论为无法证实这些药物对COVID-19住院结局的获益,且各方案与住院生存率下降及室性心律失常频率增加相关。该文已撤稿。

要点

  • 多国注册分析纳入96032例COVID-19住院患者,其中14888例接受羟氯喹或氯喹(单用或联用大环内酯类),81144例为对照组。
  • 校正混杂因素后,羟氯喹组住院死亡率18.0%(HR 1.335,95%CI 1.223-1.457)、羟氯喹联合大环内酯组23.8%(HR 1.447,95%CI 1.368-1.531),均高于对照组9.3%。
  • 氯喹组住院死亡率16.4%(HR 1.365,95%CI 1.218-1.531)、氯喹联合大环内酯组22.2%(HR 1.368,95%CI 1.273-1.469),均高于对照组9.3%。
  • 新发室性心律失常:羟氯喹组6.1%(HR 2.369,95%CI 1.935-2.900)、羟氯喹联合大环内酯组8.1%(HR 5.106,95%CI 4.106-5.983),均高于对照组0.3%。
  • 氯喹组新发室性心律失常4.3%(HR 3.561,95%CI 2.760-4.596)、氯喹联合大环内酯组6.5%(HR 4.011,95%CI 3.344-4.812),均高于对照组0.3%。

适用人群与场景

  • 纳入2019年12月20日至2020年4月14日期间住院、SARS-CoV-2实验室检测阳性的患者,数据来自6大洲671家医院。
  • 诊断后48小时内接受氯喹单用、氯喹联合大环内酯、羟氯喹单用或羟氯喹联合大环内酯之一者纳入相应治疗组,未接受这些治疗者纳入对照组。
  • 排除诊断48小时后或机械通气期间启动目标治疗者,以及接受瑞德西韦者。

研究设计与关键结果

  • 多国注册分析,纳入96032例COVID-19住院患者(平均年龄53.8岁,46.3%为女性),来自6大洲671家医院。
  • 治疗组共14888例:氯喹1868例、氯喹联合大环内酯3783例、羟氯喹3016例、羟氯喹联合大环内酯6221例;对照组81144例。
  • 住院期间死亡10698例(11.1%);校正年龄、性别、种族或族裔、体重指数、基础心血管疾病及其危险因素、糖尿病、基础肺病、吸烟、免疫抑制状态及基线疾病严重程度后,各治疗组住院死亡率均高于对照组(9.3%):羟氯喹18.0%(HR 1.335,95%CI 1.223-1.457)、羟氯喹联合大环内酯23.8%(HR 1.447,95%CI 1.368-1.531)、氯喹16.4%(HR 1.365,95%CI 1.218-1.531)、氯喹联合大环内酯22.2%(HR 1.368,95%CI 1.273-1.469),均与住院死亡风险升高独立相关。
  • 新发室性心律失常(非持续性或持续性室性心动过速或心室颤动)发生率:对照组0.3%,羟氯喹组6.1%(HR 2.369,95%CI 1.935-2.900)、羟氯喹联合大环内酯组8.1%(HR 5.106,95%CI 4.106-5.983)、氯喹组4.3%(HR 3.561,95%CI 2.760-4.596)、氯喹联合大环内酯组6.5%(HR 4.011,95%CI 3.344-4.812),均与住院期间新发室性心律失常风险升高独立相关。

证据类型、等级与局限

  • 证据类型:多国注册研究分析(观察性研究)。
  • 该文已撤稿(RETRACTED)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:无法证实羟氯喹或氯喹单用或联用大环内酯类对COVID-19住院结局的获益,且各方案与住院生存率下降及室性心律失常频率增加相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.

METHODS: We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide), and patients who received none of these treatments formed the control group. Patients for whom one of the treatments of interest was initiated more than 48 h after diagnosis or while they were on mechanical ventilation, as well as patients who received remdesivir, were excluded. The main outcomes of interest were in-hospital mortality and the occurrence of de-novo ventricular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).

FINDINGS: 96 032 patients (mean age 53·8 years, 46·3% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria. Of these, 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group. 10 698 (11·1%) patients died in hospital. After controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity), when compared with mortality in the control group (9·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·223-1·457), hydroxychloroquine with a macrolide (23·8%; 1·447, 1·368-1·531), chloroquine (16·4%; 1·365, 1·218-1·531), and chloroquine with a macrolide (22·2%; 1·368, 1·273-1·469) were each independently associated with an increased risk of in-hospital mortality. Compared with the control group (0·3%), hydroxychloroquine (6·1%; 2·369, 1·935-2·900), hydroxychloroquine with a macrolide (8·1%; 5·106, 4·106-5·983), chloroquine (4·3%; 3·561, 2·760-4·596), and chloroquine with a macrolide (6·5%; 4·011, 3·344-4·812) were independently associated with an increased risk of de-novo ventricular arrhythmia during hospitalisation.

INTERPRETATION: We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.

FUNDING: William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Mehra MR, Desai SS, Ruschitzka F, et al. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. PMID: 32450107. doi:10.1016/S0140-6736(20)31180-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。